EphA2-derived peptide vaccine with amphiphilic poly(γ-glutamic acid) nanoparticles elicits an anti-tumor effect against mouse liver tumor

Cancer Immunology, Immunotherapy

Volumn 59, Issue 5, 2010, Pages 759-767

  Yamaguchi, Shinjiro ^a,c   Tatsumi, Tomohide ^a,c   Takehara, Tetsuo ^a,c   Sasakawa, Akira ^a,c   Yamamoto, Masashi ^a,c   Kohga, Keisuke ^a   Miyagi, Takuya ^a   Kanto, Tatsuya ^a   Hiramastu, Naoki ^a   Akagi, Takami ^b,c   Akashi, Mitsuru ^b,c   Hayashi, Norio ^a,c  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Acquired immunity; EphA2 derived peptide; Liver tumor; Peptide vaccine

Indexed keywords

ALANINE AMINOTRANSFERASE; EPHRIN RECEPTOR A2; FREUND ADJUVANT; NANOPARTICLE; OVALBUMIN; PEPTIDE VACCINE; POLYGLUTAMIC ACID; TUMOR ANTIGEN; CANCER VACCINE; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT; POLY(GAMMA GLUTAMIC ACID); POLY(GAMMA-GLUTAMIC ACID); SUBUNIT VACCINE; SURFACTANT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; GENE OVEREXPRESSION; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LIVER INJURY; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN IMMOBILIZATION; SPLEEN CELL; TUMOR GROWTH; ANIMAL; C57BL MOUSE; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; FEMALE; FREUND'S ADJUVANT; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL; NANOPARTICLES; POLYGLUTAMIC ACID; RECEPTOR, EPHA2; SURFACE-ACTIVE AGENTS; VACCINES, SUBUNIT;

EID: 77950508445     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0796-2     Document Type: Article

References (45)

1. Berzofsky JA, Ahlers JD, Belyakov IM (2001) Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1:209-219
2. Schijns VE (2000) Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 12:456-463
3. Valmori D, Souleimanian NE, Tosello V et al (2007) Vaccination with NY-ESO-1 protein and CPG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 104:8947-8952
4. Wang F, Bade E, Kuniyoshi C et al (1999) Phase 1 trial of a MART-1 peptide vaccine with incomplete Freund's adjuvants for resected high-risk melanoma. Clin Cancer Res 5:2756-2765
5. Gilewski TA, Ragupathi G, Dickler M et al (2007) Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21. Clin Cancer Res 13:2977-2985
6. Bottomley A, Debruyne C, Ferip E et al (2008) Symptom and quality of life results of an international randomized phase 3 study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer 44:2178-2184
7. Perales MA, Yuan J, Powel S et al (2008) Phase 1/2 study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma. Mol Ther 16:2022-2029
8. Mocellin S, Riccardo-Rossi C, Lise M et al (2004) Colorectal cancer vaccines: principles, results, and perspectives. Gastroenterology 27:1821-1837
9. Dinauer N, Balthasar S, Weber C et al (2005) Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 26:5898-5906
10. Khatri K, Goyal AK, Gupta N et al (2008) Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int J Pharm 354:235-241
11. Almeida AJ, Souto E (2007) Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv Drug Deliv Rev 59:478-490
12. Hayakawa T, Kawamura M, Okamoto M et al (1998) Concanavalin A-immobilized polystyrene nanospheres capture HIV-1 and gp120: potential approach towards prevention of viral transmission. J Med Virol 56:327-331
13. Kawamura M, Naito T, Ueno M et al (2002) Induction of mucosal IgA following intravaginal administration of inactivated HIV-1-capturing nanospheres in mice. J Med Virol 66:291-298
14. Akagi T, Kawamura M, Ueno M et al (2003) Mucosal immunization with inactivated HIV-1-capturing nanospheres induces a significant HIV-1-specific vaginal antibody response in mice. J Med Virol 69:163-172
15. Miyake A, Akagi T, Enose Y et al (2004) Induction of HIVspecific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques. J Med Virol 73:368-377
16. Akagi T, Wang X, Uto T, Baba M, Akashi M (2007) Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 28:3427-3436
17. Shih IL, Van YT (2001) The production of poly-(γ-glutamic acid) from microorganisms and its various applications. Bioresour Technol 79:207-225
18. Obst M, Steinbüchel A (2004) Microbial degradation of poly(amino acid)s. Biomacromolecules 5:1166-1176
19. Sung MH, Park C, Kim CJ, Poo H, Soda K, Ashiuchi M (2005) Natural and edible biopolymer poly-γ-glutamic acid: synthesis, production, and applications. Chem Rec 5:352-366
20. Akagi T, Higashi M, Kaneko T et al (2005) In vitro enzymatic degradation of nanoparticles prepared from hydrophobically-modified poly(γ-glutamic acid). Macromol Biosci 14:598-602
21. Akagi T, Kaneko T, Kida T, Akashi M (2006) Multifunctional conjugation of proteins on/into bio-nanoparticles prepared by amphiphilic poly(γ- glutamic acid). J Biomater Sci Polym Ed 17:875-892
22. Uto T, Wang X, Sato K et al (2007) Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 178:2979-2986
23. Olson RM, Perencevich NP, Malcolm AW et al (1980) Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum. Cancer 45:2969-2974
24. Malcolm AW, Perencevich NP, Olson. RM et al (1981) Analysis of recurrence patterns following curative resection for carcinoma of the colon and rectum. Surg Gynecol Obstet 152:131-136
25. Yamaguchi S, Tatsumi T, Takehara T et al (2007) Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer 110:1469-1477
26. Yamaguchi S, Tatsumi T, Takehara T et al (2008) Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity. Cancer Immunol Immunother 57:1861-1869
27. Akagi T, Kaneko T, Kida T et al (2005) Preparation and characterization of biodegradable nanoparticles based on poly(γ-glutamic acid) with L-phenylalanine as a protein carrier. J Control Release 108:226-236
28. Tatsumi T, Gambotto A, Robbins PD et al (2002) Interleukin 18-gene transfer expands the repertoire of anti-tumor Th1-type immunity elicited by dendritic cell- based vaccines in association with enhanced therapeutic efficacy. Cancer Res 62:5853-5858
29. Yoshikawa T, Okada N, Oda A et al (2008) Development of amphiphilic γ-PGA-nanoparticle based tumor vaccine: potential of the nanoparticle cytosolic protein delivery carrier. Biochem Biophys Res Commun 366:408-413
30. Yoshikawa T, Okada N, Oda A et al (2008) Nanoparticles built by self-assembly of amphiphilic γ-PGA can deliver antigens to antigen-presenting cells with high efficiency: a new tumor-vaccine carrier for eliciting effector T cells. Vaccine 26:1303-1313
31. Uto T, Wang X, Akagi T et al (2009) Improvement of adaptive immunity by antigen-carrying biodegradable nanoparticles. Biochem. Biophys Res Commun 379:600-604413
32. Dhodapkar MV, Young JW, Chapman PB et al (2006) Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Clin Cancer Res 6:4831-4838
33. Zantek ND, Azimi M, Fedor-Chaiken M, Wang B, Brackenbury R, Kinch MS (1999) E-cadherin regulates the function of the EphA2 receptor tyrosine kinase. Cell Growth Differ 10:629-638
34. DeRisi J, Penland L, Brown PO et al ( 1996) Use of a cDN A microarray to analyse gene expression patterns in human cancer. Nat Genet 14:457-460
35. Easty DJ, Hill SP, Hsu MY etal (1999) Up-regulation of ephrinA1 during melanoma progression. Int J Cancer 84:494-501
36. Lu M, Miller KD, Gokmen-Polar Y, Jeng MH, Kinch MS (2003) EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity. Cancer Res 63:3425-3429
37. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS (2001) EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res 61:2301-2306
38. Branan JM, Dong W, Prudkin L et al (2009) Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 15:4423-4430
39. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 23:1448-1456
40. D'Amico TA, Aloia TA, Moore MB et al (2001) Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg 72:1144-1148
41. Broderson JR (1989) A retrospective review of lesions associated with the use of Freund's adjuvant. Lab Anim Sci 39:400-405
42. Amyx HL (1987) Control of animal pain and distress in antibody production and infectious disease studies. J Am Vet Med Assoc 191:1287-1289
43. Toth LA, Dunlap AW, Olson GA et al (1989) An evaluation of distress following intraperitoneal immunization with Freund' adjuvant in mice. Lab Anim Sci 39:122-126
44. George AP, Catherine AP (2005) Liver immunobiology. Toxicol Pathol 33:52-62
45. Doherty DG, O'Farrelly C (2000) Innate and adaptive lymphoid cells in human liver. Immunol Rev 174:5-20